Gene Therapy Approaches to Functional Cure and Protection of Hematopoietic Potential in HIV Infection

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2019 Mar 14

PMID 30862061

Citations 3

Authors

Tetsuo Tsukamoto

Affiliations

Soon will be listed here.

Abstract

Although current antiretroviral drug therapy can suppress the replication of human immunodeficiency virus (HIV), a lifelong prescription is necessary to avoid viral rebound. The problem of persistent and ineradicable viral reservoirs in HIV-infected people continues to be a global threat. In addition, some HIV-infected patients do not experience sufficient T-cell immune restoration despite being aviremic during treatment. This is likely due to altered hematopoietic potential. To achieve the global eradication of HIV disease, a cure is needed. To this end, tremendous efforts have been made in the field of anti-HIV gene therapy. This review will discuss the concepts of HIV cure and relative viral attenuation and provide an overview of various gene therapy approaches aimed at a complete or functional HIV cure and protection of hematopoietic functions.

Citing Articles

Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease.

Ernst M, Broeders M, Herrero-Hernandez P, Oussoren E, van der Ploeg A, Pijnappel W Mol Ther Methods Clin Dev. 2020; 18:532-557.

PMID: 32775490 PMC: 7393410. DOI: 10.1016/j.omtm.2020.06.022.

Hematopoietic Stem/Progenitor Cells and the Pathogenesis of HIV/AIDS.

Tsukamoto T Front Cell Infect Microbiol. 2020; 10:60.

PMID: 32154191 PMC: 7047323. DOI: 10.3389/fcimb.2020.00060.

Novel Approaches for the Delivery of Anti-HIV Drugs-What Is New?.

das Neves J Pharmaceutics. 2019; 11(11).

PMID: 31661775 PMC: 6921055. DOI: 10.3390/pharmaceutics11110554.

References

Marandin A, Katz A, Oksenhendler E, Tulliez M, Picard F, Vainchenker W . Loss of primitive hematopoietic progenitors in patients with human immunodeficiency virus infection. Blood. 1996; 88(12):4568-78. View

Tsukamoto T, Yamamoto H, Okada S, Matano T . Recursion-based depletion of human immunodeficiency virus-specific naive CD4(+) T cells may facilitate persistent viral replication and chronic viraemia leading to acquired immunodeficiency syndrome. Med Hypotheses. 2016; 94:81-5. DOI: 10.1016/j.mehy.2016.06.024. View

McMichael A . Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take? Could a CD8 T-Cell Vaccine Prevent Persistent HIV Infection?. Cold Spring Harb Perspect Biol. 2017; 10(9). PMC: 6005744. DOI: 10.1101/cshperspect.a029124. View

Liu L, Patel B, Ghanem M, Bundoc V, Zheng Z, Morgan R . Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. J Virol. 2015; 89(13):6685-94. PMC: 4468509. DOI: 10.1128/JVI.00474-15. View

Sather B, Romano Ibarra G, Sommer K, Curinga G, Hale M, Khan I . Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med. 2015; 7(307):307ra156. PMC: 4790757. DOI: 10.1126/scitranslmed.aac5530. View

Cyranoski D, Ledford H . Genome-edited baby claim provokes international outcry. Nature. 2018; 563(7733):607-608. DOI: 10.1038/d41586-018-07545-0. View

Hong F, Mellors J . Changes in HIV reservoirs during long-term antiretroviral therapy. Curr Opin HIV AIDS. 2014; 10(1):43-8. PMC: 4567251. DOI: 10.1097/COH.0000000000000119. View

Wolstein O, Boyd M, Millington M, Impey H, Boyer J, Howe A . Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol Ther Methods Clin Dev. 2015; 1:11. PMC: 4365823. DOI: 10.1038/mtm.2013.11. View

Tebas P, Stein D, Tang W, Frank I, Wang S, Lee G . Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10):901-10. PMC: 4084652. DOI: 10.1056/NEJMoa1300662. View

10.

Symonds G, Johnstone H, Millington M, Boyd M, Burke B, Breton L . The use of cell-delivered gene therapy for the treatment of HIV/AIDS. Immunol Res. 2010; 48(1-3):84-98. DOI: 10.1007/s12026-010-8169-7. View

11.

Nielsen S, Clark D, Hutchings M, Dam-Larsen S, Repping S, Nielsen J . Treatment with granulocyte colony-stimulating factor decreases the capacity of hematopoietic progenitor cells for generation of lymphocytes in human immunodeficiency virus-infected persons. J Infect Dis. 1999; 180(6):1819-26. DOI: 10.1086/315136. View

12.

Piras F, Riba M, Petrillo C, Lazarevic D, Cuccovillo I, Bartolaccini S . Lentiviral vectors escape innate sensing but trigger p53 in human hematopoietic stem and progenitor cells. EMBO Mol Med. 2017; 9(9):1198-1211. PMC: 5582409. DOI: 10.15252/emmm.201707922. View

13.

Higaki K, Hirao M, Kawana-Tachikawa A, Iriguchi S, Kumagai A, Ueda N . Generation of HIV-Resistant Macrophages from IPSCs by Using Transcriptional Gene Silencing and Promoter-Targeted RNA. Mol Ther Nucleic Acids. 2018; 12:793-804. PMC: 6111070. DOI: 10.1016/j.omtn.2018.07.017. View

14.

Uchida N, Sutton R, Friera A, He D, Reitsma M, Chang W . HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc Natl Acad Sci U S A. 1998; 95(20):11939-44. PMC: 21744. DOI: 10.1073/pnas.95.20.11939. View

15.

de Ravin S, Wu X, Moir S, Anaya-OBrien S, Kwatemaa N, Littel P . Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2016; 8(335):335ra57. PMC: 5557273. DOI: 10.1126/scitranslmed.aad8856. View

16.

Petit N, Baillou C, Burlion A, Dorgham K, Levacher B, Amiel C . Gene transfer of two entry inhibitors protects CD4⁺ T cell from HIV-1 infection in humanized mice. Gene Ther. 2015; 23(2):144-50. DOI: 10.1038/gt.2015.101. View

17.

Nasimuzzaman M, Lynn D, Ernst R, Beuerlein M, Smith R, Shrestha A . Production and purification of high-titer foamy virus vector for the treatment of leukocyte adhesion deficiency. Mol Ther Methods Clin Dev. 2016; 3:16004. PMC: 5052019. DOI: 10.1038/mtm.2016.4. View

18.

Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L . Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009; 360(5):447-58. DOI: 10.1056/NEJMoa0805817. View

19.

Manotham K, Chattong S, Setpakdee A . Generation of CCR5-defective CD34 cells from ZFN-driven stop codon-integrated mesenchymal stem cell clones. J Biomed Sci. 2015; 22:25. PMC: 4379539. DOI: 10.1186/s12929-015-0130-6. View

20.

Balazs A, Chen J, Hong C, Rao D, Yang L, Baltimore D . Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2011; 481(7379):81-4. PMC: 3253190. DOI: 10.1038/nature10660. View